Feb 22, 2022
Jeffrey Peppercorn, MD, MPH, has been appointed as the next editor-in-chief of JCO Oncology Practice (JCO OP), an ASCO journal. JCO OP publishes impactful information and insights to keep oncology practice current on changes and challenges inherent in delivering equitable, high-quality oncology care with an evolving value-based lens.
“I am delighted that Dr. Peppercorn has accepted this opportunity to lead JCO Oncology Practice,” said ASCO president Everett E. Vokes, MD, FASCO. “He is a highly accomplished oncologist who has demonstrated excellence in research and analyzing issues such as quality of care, cost, and access to care. He understands the numerous strengths of the journal and the factors necessary to grow its reach as a premier cancer publication.”
Dr. Peppercorn is a medical oncologist who specializes in breast cancer at Massachusetts General Hospital (MGH) Cancer Center in Boston, MA. His academic work involves both research and analysis of issues of health care delivery, access to care, cost, policy, and bioethics. Dr. Peppercorn served as chair of the Ethics Committee of the Alliance for Clinical Trials in Oncology for over a decade and led the taskforce that founded the Value in Cancer Care Committee of the Alliance. While serving in multiple roles related to health services research within ASCO and the Alliance, he also participated in multiple Institute of Medicine panels on issues of cost and access to care.
Currently the inaugural director of supportive care and survivorship for the MGH Cancer Center, Dr. Peppercorn was also the founding director of the Duke Cancer Institute Survivorship Program. In these roles, he has been engaged in both research and quality improvement initiatives. Dr. Peppercorn has been involved in international efforts to address cost of cancer care and participated in the taskforce that produced ASCO’s value framework. He has authored or co-authored over 150 papers.
“Dr. Peppercorn’s expertise gives him a broad view that will enable him to continue the journal’s development by helping oncology professionals stay current in the face of new challenges and a rapidly changing care delivery system,” said ASCO CEO Clifford A. Hudis, MD, FACP, FASCO. “We are proud to warmly welcome him to JCO Oncology Practice as editor-in-chief.”
Dr. Peppercorn received his medical degree from Harvard Medical School. He completed his residency in internal medicine at MGH and his fellowship in hematology/oncology in the Dana Farber Cancer Institute/MGH combined program and in medical ethics at Harvard Medical School. He graduated magna cum laude from Harvard College in History and Science and continues to teach at Harvard Medical School.
“I am extremely excited to lead JCO Oncology Practice as its next editor-in-chief and grateful to ASCO for this opportunity. This journal is dedicated to addressing the challenges and opportunities we face in delivering high-quality, accessible cancer care to all patients,” said Dr. Peppercorn. “I look forward to working with my colleagues on the JCO OP staff and editorial board to making this the premier oncology journal for health services, care delivery, quality, ethics, and policy research and continuing its role as essential reading for every oncology clinician.”
Dr. Peppercorn will begin serving as the editor designee of JCO OP on March 1, 2022, and as editor-in-chief on September 1.